example 10 [CN110740999A]   Click here for help

GtoPdb Ligand ID: 12952

Synonyms: compound 40 [PMID: 34323489] [4]
Compound class: Synthetic organic
Comment: This chemical structure was extracted from a patent claiming fourth generation EGFR inhibitors [2]. Based on a chemical structure that was submitted to the Cambridge Crystallographic Data Centre (Deposition number 2261855), and in the absence of a disclosed name-to-structure, we predict that this is likely to be the clinical lead EGFR inhibitor BBT-176 (or is closely related to it) as written about in [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 11
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 122.28
Molecular weight 601.17
XLogP 1.65
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CN1CCN(CC1)C2CCN(CC2)C3=CC=C(C(=C3)OC)NC4=NC(=C(C=N4)Cl)NC5=C(C=CC=C5)NS(=O)(=O)C
Isomeric SMILES COC1=C(NC2=NC=C(Cl)C(NC3=CC=CC=C3NS(C)(=O)=O)=N2)C=CC(=C1)N4CCC(CC4)N5CCN(C)CC5
InChI InChI=1S/C28H37ClN8O3S/c1-35-14-16-37(17-15-35)20-10-12-36(13-11-20)21-8-9-25(26(18-21)40-2)32-28-30-19-22(29)27(33-28)31-23-6-4-5-7-24(23)34-41(3,38)39/h4-9,18-20,34H,10-17H2,1-3H3,(H2,30,31,32,33)
InChI Key MPISIZFSGAZROV-UHFFFAOYSA-N
References
1. He J, Zhou Z, Sun X, Yang Z, Zheng P, Xu S, Zhu W. (2021)
The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.
Eur J Med Chem, 210: 112995. [PMID:33243531]
2. Lee KH, Xin R, Cui J, Cai Z, Choi HJ, Zheng M, Tian B, Zhao B, Park C, Jin H, Daugirala KB. (2020)
N2, N4-diphenylpyrimidine-2, 4-diamine derivative, process for producing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient.
Patent number: CN110740999A. Assignee: Korea Institute Of Chemistry Korea Research Institute of Chemical Technology KRICT. Priority date: 12/06/2018. Publication date: 31/01/2020.
3. Lim SM, Fujino T, Kim C, Lee G, Lee YH, Kim DW, Ahn JS, Mitsudomi T, Jin T, Lee SY. (2023)
BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.
Clin Cancer Res, 29 (16): 3004-3016. [PMID:37249619]
4. Shaikh M, Shinde Y, Pawara R, Noolvi M, Surana S, Ahmad I, Patel H. (2022)
Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.
J Med Chem, 65 (2): 1008-1046. [PMID:34323489]